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Abstract
Background: Critical to the development of molecular signatures from microarray and other high-throughput data is
testing the statistical significance of the produced signature in order to ensure its statistical reproducibility. While current
best practices emphasize sufficiently powered univariate tests of differential expression, little is known about the factors
that affect the statistical power of complex multivariate analysis protocols for high-dimensional molecular signature
development.
Methodology/Principal Findings: We show that choices of specific components of the analysis (i.e., error metric, classifier,
error estimator and event balancing) have large and compounding effects on statistical power. The effects are
demonstrated empirically by an analysis of 7 of the largest microarray cancer outcome prediction datasets and
supplementary simulations, and by contrasting them to prior analyses of the same data.
Conclusions/Significance: The findings of the present study have two important practical implications: First, high-
throughput studies by avoiding under-powered data analysis protocols, can achieve substantial economies in sample
required to demonstrate statistical significance of predictive signal. Factors that affect power are identified and studied.
Much less sample than previously thought may be sufficient for exploratory studies as long as these factors are taken into
consideration when designing and executing the analysis. Second, previous highly-cited claims that microarray assays may
not be able to predict disease outcomes better than chance are shown by our experiments to be due to under-powered
data analysis combined with inappropriate statistical tests.
Citation: Aliferis CF, Statnikov A, Tsamardinos I, Schildcrout JS, Shepherd BE, et al. (2009) Factors Influencing the Statistical Power of Complex Data Analysis
Protocols for Molecular Signature Development from Microarray Data. PLoS ONE 4(3): e4922. doi:10.1371/journal.pone.0004922
Editor: Vladimir B. Bajic, University of the Western Cape, South Africa
Received July 18, 2008; Accepted February 5, 2009; Published March 17, 2009
Copyright:  2009 Aliferis et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work was in part supported by grant 2R56LM007948-04A1. The funding agencies had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: constantin.aliferis@nyumc.org
Introduction
Microarrays and other high-throughput assaying technologies
have generated immense opportunities for discovery spanning the
spectrum from basic research to clinical studies [1–3]. As the field
moves from simpler analyses (e.g., differential expression of single
genes and clustering) to more complex analyses such as developing
multivariate molecular signatures in supervised fashion, the
interpretation of microarray data involves multifaceted analysis
protocols with many sophisticated and interacting analytic steps
[4]. Developing molecular signatures in particular, is playing an
increasingly important role in a variety of research design
objectives both in basic and translational studies. Such objectives
include, for example, detecting complex and coordinated patterns
of transcriptional response to chemotherapeutic agents on cell lines
and predicting subsequent patient treatment response on the basis
of this information [5], discovery of new drug targets [6], discovery
of biomarkers [7], subtyping diseases [8] and personalizing
treatments [9].
The reproducibility of gene expression microarrays across
laboratories for individual gene expression measurements and
the ability to differentiate between disease subtypes are well
established in recent studies [2,10,11]. Essential to developing
molecular signatures is not only assay reproducibility however, but
also statistical reproducibility. The latter can be directly assessed by
tests of statistical significance of the produced signatures. These
tests are usually permutation based and were introduced in
bioinformatics by [12,13] based on foundational works of [14,15].
Although substantial efforts have been invested in studying the
statistical power of differential gene expression [16,17], much less
is known currently about the power of testing molecular signatures
for statistically significant (hence reproducible, ‘‘real’’) signal. The
present work shows that four specific components of data analysis
(error metric, error estimator, classifier, and event balancing) have
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power) to detect true signal in molecular signatures. These findings
can help researchers design data analysis protocols that require
fewer samples; they also shed light on the appropriateness of
microarrays as an assay platform for outcome prediction. The
present report uses theoretical analysis, simulation experiments,
and empirical analysis of 7 human gene expression datasets
[8,9,18–22]. The datasets were chosen so that the comparison to a
previously published highly-cited protocol [23] constitutes a case
study that demonstrates the practical benefits of improved
statistical power on the resource efficiency and validity of analysis.
Results
We start with a theoretical analysis that shows how the choice of
four specific components of data analysis protocols for molecular
signature development and their statistical testing affects the
statistical power to detect predictive signal. We then present a
simulation study that demonstrates that depending on choice of
the above components even strong signals can fail to be detected
with routine sample sizes and that the effects of each component
on statistical power are large and compounded. We subsequently
test the insights and hypotheses generated by the theoretical
analysis and simulation studies with real gene expression data.
Specifically, we analyze 7 datasets [8,9,18–22]. These datasets are
important for two reasons: first, they have been used to derive both
clinically relevant signatures and to investigate underlying
biological processes [8,9,18,20–22,24]. Second, a highly-cited
prior analysis of the same datasets [23] reached the conclusion that
statistically significant signal cannot be detected in 5 out of 7
datasets and thus either microarrays are incapable of predicting
clinical outcomes (and by extension, giving insight into the biology
of disease progression) or that studies with a few hundred samples
are insufficient and only sample sizes in the order of thousands will
lead to statistically reproducible findings [25,26]. Our investigation
into the factors that affect power allows us to test the hypothesis
that these prior results were due in large part to an underpowered
analysis protocol, showing thus the great importance of careful
planning of data analytics with an eye toward sufficient power.
Theoretical analysis
Effects of error metric on power. Fundamental to the
assessment of predictive signal of molecular signatures is the choice
of error metric that is used to quantify predictivity. An unfortunate
frequent practice in the field of bioinformatics to date is to use as
classification performance metric the proportion of
misclassifications. Discontinuous error metrics such as proportion
of misclassifications, sensitivity, and specificity are ‘‘improper
scoring rules’’ however, since they impose arbitrary thresholds on
predictor models and do not capture the uncertainty in the
predictions [27]. The proportion of misclassifications moreover, is
known to yield estimators with low power to detect signals in data
when compared to other metrics such as area under the receiver
operating characteristic (ROC) curve (AUC) [27]. The ROC
curve is the plot of sensitivity versus 1-specificity for a range of
continuous or discrete classification threshold values. AUC is
equivalent to a rank correlation between predicted outcome
probability and the observed outcome, requiring no
categorization. AUC ranges from 0 to 1, with an AUC equal to
0 indicating the worst possible classifier, 0.5 representing a random
(i.e., uninformative) classifier, and 1 representing perfect
classification. Testing whether predictions are unrelated to true
outcomes using AUC is equivalent to the Wilcoxon test, while
testing for proportion of misclassifications is equivalent to using the
Mood median test which has been shown to have poor efficiency
compared to the Wilcoxon test [28]. A broader, non-parametric
justification why AUC is more discriminative than proportion of
misclassifications is provided by [29]. Supporting Information File
S1 provides an example where two signatures have the same
proportions of misclassifications but different predictivity which is
captured by the AUC metric. Although counter-examples do exist,
they are relatively rarer [29]. Hence the AUC is more powerful
than proportion of misclassifications.
Effects of classifier on power. Statistical power is increased
whenever the tested effect size (predictivity in our context) is larger
and the variance is smaller (assuming fixed sample size for
simplicity). Hence using a classifier that produces the most
predictive signature (everything else being equal) directly
translates to improved statistical power for detecting predictive
signal. Statistical machine learning theory proves that different
classifiers have different inductive biases (i.e., preferences for
classes of models), and that a classifier family has to be matched to
the characteristics of the domain in order to achieve optimal
predictivity (and correspondingly optimal power to detect signal)
[30]. Indeed, recent empirical studies with gene expression data
have shown that specific classifiers, such as Support Vector
Machines (SVMs) produce models with stronger predictive ability
(signal) and higher robustness across many high-throughput
datasets compared to several widely-used alternatives [31–33].
Other authors also corroborate the need to choose classifiers
carefully by recommending against some complex classifiers in
order to avoid overfitting [4]. The above results have been
neglected by some authors [23] who claim that ‘‘in principle, there is
no biological or mathematical reason why one particular classification method
should be better than others’’ and do not optimize the choice of
classifier for the data at hand when conducting statistical testing of
microarray gene expression signatures. We will show that this
adversely affects the power of their analyses.
Effects of error estimator on power. Procedures that
estimate the generalization error of a signature are called ‘‘error
estimators’’. A commonly used estimator is the holdout estimator.
The holdout estimator is based on splitting the data in two random
non-overlapping parts, deriving a signature from the first one and
assessing its error in the second one. The holdout estimator is
asymptotically unbiased, that is, with infinite test sample it
produces an estimate that is the true error in the population. In
small samples holdout estimates often deviate from the large-
sample value. This variability is reduced as sample size grows [34].
From standard power-size analysis considerations it follows that
the lowest-variance unbiased estimator has highest power [35].
Unfortunately, the holdout estimator has larger variance com-
pared to several other unbiased estimators used in molecular
signature studies [34], and this naturally leads to reduced statistical
power. We elaborate on the reasons for this behavior by
comparing the holdout to the repeated 10-fold cross-validation estimator
[36]. The latter estimator is a variant of the well-known 10-fold
cross-validation estimator which is calculated by balanced splitting
of the data into 10 non-overlapping sample sets used for testing
(while each complementing set is used for training) and averaging
the test errors. The repeated 10-fold cross-validation estimator is
obtained by running regular 10-fold cross-validation for 100 (or
other sufficient number of) times with different splits of data into
training and testing sets each time and by reporting the average
estimate over all runs.
To see why holdout has higher variance than repeated 10-fold
cross-validation, consider that there are several major sources of
variance of estimators in practical use. These are: sampling variance,
split variance, testing set size, and internal variance. Sampling variance
Power Molecular Signatures
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of fixed finite size from a population. Split variance refers to
uncertainty associated with drawing a random split of training and
testing sets from all possible splits of a given sample with fixed
training-testing ratio. Testing set size variance refers to variability
in error estimates due to finite testing dataset size. Finally, internal
variance refers to uncertainty associated with classifier instability
(i.e., different training datasets lead to different signatures) and
increases as training set size decreases [30,36]. The repeated 10-
fold cross-validation essentially eliminates split variance by using
many splits and averaging over them, and furthermore it reduces
internal variance by using more sample for training than holdout
(under typical training-testing split ratios). Both estimators have
the same sampling variance. Finally, while testing set size variance
is larger in the repeated 10-fold estimator than the holdout, the
combination of higher split and internal variance makes overall
the holdout to have higher variance and to be less powerful than
repeated 10-fold cross-validation in many practical situations.
Unfortunately this is often neglected in practical analysis and
therefore using the holdout estimator leads to reduced ability to
establish statistical significance of signatures.
Effects of event balancing on power. When in the context
of error estimation one enforces that both the training and testing
sets have the same proportion of events and non-events as the
original full data, we will call such error estimation ‘‘event
balanced’’. An important and subtle shortcoming of some data
analysis protocols is to not balance the training and testing data,
seriously affecting variance, statistical power (and potentially
biasing error estimates). For example, in [23] the models were
trained on samples with 50% event rates. They were then tested
on samples the event prevalence of which was far below 50% thus
yielding estimates that were less efficient than the standard holdout
estimator in which the data are split at random. The result of this
is evident in Figure 2 from [23] in which as the sampling moves to
larger training sets, this forces the testing sets in addition to being
smaller, to implicitly have a very low event rate and thus large
variance of error estimates. Notice that most classifiers, including
the one used by [23], are designed to work under the assumption
that the training and testing sets are identically distributed [30]. It
is thus unrealistic to expect in general that a classifier that is
trained using data from a distribution where events and non-
events are equally likely will perform well, without adjustments
[37], in a different distribution where this ratio is heavily distorted.
This is especially so when using an error metric that is sensitive to
event priors such as proportion of misclassifications. Supporting
Information File S2 shows via an example that this shift in
distributions can affect the performance of even an optimal
classifier, i.e., one that has learned perfectly the distribution of the
training data, to the point of appearing to be no better than
flipping a coin.
Simulation experiments
A primary purpose of the simulation experiments is to
demonstrate and study the relative importance of the above
factors that are hypothesized on the previous theoretical grounds
to influence power of complex data analysis of high-throughput
data. The simulation uses an idealized analysis in which the data-
generating process is known and the true moderate-strength signal
is present even in small samples. Such analysis is typical in
literature discussing statistical issues surrounding microarray data
because knowing the generative model allows a precise charac-
terization of the strengths and limitations of data analysis
techniques [38]. Details of the simulation are provided in the
Supporting Information File S3. A second goal is to examine the
statistical power of a previously published data analysis protocol
[23] (‘‘Protocol I’’, that employs non-balanced holdout estimator
with proportion of correct classifications and a nearest-centroid
classifier), specifically when varying these four factors. Finally, a
third goal is to test the relative power of the theoretically expected
more powerful protocol (‘‘Protocol II’’, that employs balanced
repeated 10-fold cross-validation estimator with AUC as the error
metric and SVMs as classifier). The best protocol in the
simulations will then be validated in the next sub-section with
real data.
The left part of Figure 1 demonstrates the inability of Protocol I
[23] to detect signal which is detectable by Protocol II. The right
part of this figure shows results of application of Protocol II and
assessment of its statistical significance by permutation testing
(details about statistical significance testing are provided in the
Materials and Methods section). Overall Protocol I has remarkably
small power ranging from less than 0.002 to 0.3 (depending on the
criterion used for rejecting the null hypothesis, please see
Supporting Information File S3). In contrast, Protocol II has
power 0.93. By replacing proportion of misclassifications with
AUC in Protocol I, its power increases to 0.6, and by additionally
adding the use of SVMs, it further increases to 0.75. Conversely, if
we start with Protocol II and replace AUC with proportion of
misclassifications and SVMs with the classifier from [23], these
changes reduce the power from 0.93 to 0.46. These empirical
power estimates do not provide the exact power in real datasets
since the true nature of the corresponding distributions is not
known and varies among datasets. However the simulation
strengthens our hypothesis that the choice of error metric,
classifier, event balancing and error estimator have large impact
on study results and sheds light on the limitations of the analyses
described in prior work [23]. In the next sub-section we test the
Protocol II in real data (where Protocol I was previously
independently applied).
Analysis of real gene expression data
Figure 2 reports the AUC estimates produced with Protocol II
for each one of the 7 real datasets along with p-values for testing
the null hypothesis that the produced signatures are uninformative
(i.e., with no signal). As can be seen in Figure 2, statistically
significant signal (at the 0.05 level) can be detected in 6 out of 7
datasets compared to 2 out of 7 in the prior study that had used
the less powerful Protocol I [23]. The p-values are calculated by a
standard label-permutation procedure (see Materials and Methods
section). The histograms in Figure 2 depict with blue the
distribution of the repeated 10-fold cross-validation AUC
estimates from Protocol II for datasets produced under the null
hypothesis of ‘‘no predictive signal’’ and with red the repeated 10-
fold cross-validation AUC estimates from Protocol II for the
original datasets.
The above repeated 10-fold cross-validation AUC estimates in
the datasets that had statistically significant signal ranged from
0.67 to 0.76, indicating that even signal with weak strength can be
shown in real data to be statistically significant with moderate
sample sizes. The U-statistic based confidence intervals for
repeated 10-fold cross-validation AUC estimates are provided in
the Supporting Information File S4 and they are consistent with
the above conclusions. Notice also that under the null hypothesis
of no predictive signal the distribution of the repeated 10-fold
cross-validation AUC estimates is centered at 0.5, which
corroborates the theoretical expectation that the error estimates
are unbiased and that Protocol II does not overfit (more details in
the Supporting Information File S5).
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significance testing. The combined simulated and real data
results show very significant differences in the ability of Protocol I
and II to detect real signal. This prompted us to investigate further
the underlying differences between the two protocols. An
unanticipated finding was that a major discrepancy between the
two protocols exists in the precise null hypothesis tested: Ideally,
one wishes to test the broad null hypothesis ‘‘there is no signal in
the data’’. Rejecting this hypothesis entails that the observed signal
in the sample will generalize in the population where the sample is
drawn from. There exist several reasons why an observed signal
may not be present in the population. First, the available sample
may be non-representative of the population. Another reason is
that a splitting procedure of the sample into training and testing
parts may yield non-representative training or testing datasets (we
will refer to this as ‘‘bad’’ split of the data). The previously
published procedure for statistical significance testing of the
signatures of Protocol I (see Materials and Methods section)
eventually tests for only one source of non-reproducible signal:
‘‘bad’’ split of the sample data (and also conducts a sensitivity
analysis on the training sample size). If this procedure instead was
using sampling with replacement, it would amount to a simple
Bootstrap estimator and thus would test for a non-representative
sample as well. However because the Bootstrap introduces a bias
in the error estimates that is difficult to correct, the above
procedure samples without replacement and tests only for a
restricted null hypothesis (i.e., ‘‘bad’’ data split). In contrast, the
statistical significance procedure utilized by Protocol II (see
Materials and Methods section) uses a repeated split cross-
validation estimator effectively eliminating uncertainty
introduced by non-representative splits. In addition by
permuting labels, Protocol II effectively samples from a
population where the gene expression patterns as well as the
event rate are fixed, and there is no relationship between gene
expression patterns and outcome (hence it is equivalent to the null
hypothesis of no signal in the population). Under this label
permuting any apparent relationship between gene expression
patterns and outcomes is due to sampling variation. Thus Protocol
II tests for a much more informative null hypothesis than the
statistical test in Protocol I. Notice that the four factors affecting
power we identified earlier affect both null hypotheses and have
noteworthy effects on both protocols as shown in the simulation
studies. The null hypothesis tested by the test of significance of
Protocol I is too limited and redundant (i.e., as long as a repeated
split cross-validation estimator is used) and should not be pursued
in practice. However because of the broad implications previously
drawn by applying Protocol I, it was necessary to test it in the
present study in order to precisely identify the reasons why this
protocol failed to establish signal in real microarray datasets.
Discussion
The present work shows that several important components of
data analysis for molecular signature creation have significant and
compounding effects on probability to detect true signal (i.e.,
statistical power). Four factors (choice of error metric, classifier,
error estimator, and event balancing) were investigated by
theoretical assessment, simulation study, and application to 7
human microarray datasets.
Our findings indicate that the choices made in the data analysis
protocol corresponding to the four factors studied can improve
power and by extension research efficiency. Increasing study
sample size (as for example proposed by [26]) increases statistical
power, but also dramatically increases study costs and delays study
completion. In contrast, application of efficient statistical protocols
has the potential to significantly improve the chances of detecting
real signal with modest sample sizes. Conversely, even very large
samples can be ‘‘wasted’’ when analyzed with under-powered (i.e.,
inefficient) data analysis procedures.
Our data also shows clearly that the highly-cited study [23] that
concluded that ‘‘Five of the seven largest published studies addressing cancer
prognosis did not classify patients better than chance’’ reached these
conclusions because of two main reasons: first, the specific null
hypothesis tested was inappropriate and second, because several
Figure 1. Comparison of Protocols I and II in simulated data. Left: Example where the Protocol I [23] applied to simulated data with true
moderate-strength signal fails to detect statistical significance at all training set sizes. Right: a more powerful protocol (Protocol II, based on event
balanced repeated 10-fold cross-validation with SVM classifiers and AUC metric) detects statistically significant predictive signal according toa n
outcome-value permutation test. Specifically, the p-value of the null hypothesis of no signal is 0.0025. The blue bars depict the distribution of
repeated 10-fold cross-validation AUC estimates over 400 random datasets produced via outcome value permutation. The red line depicts the value
of repeated 10-fold cross-validation AUC on the original data (i.e., without perturbing the outcome values).
doi:10.1371/journal.pone.0004922.g001
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reasons were inextricably intertwined in the data analysis protocol
employed. The ensuing controversy in the field of disease outcome
prediction using microarrays seems thus to be an artifact of data
analysis and not an intrinsic limitation of this assaying technology.
The present findings therefore have direct positive implications for
the feasibility of related research in new drug development,
personalizing treatments and adapting clinical trials to patient
genomic characteristics. Inappropriate data analysis methodology
can create a climate of distrust about the underlying assay
technology and findings that may lead to wasteful development
processes. For example in our assessment, using a series of datasets
for validation [39–42] likely wastes time and money with no
substantial benefit. Validation using a single independent dataset
from the same population of patients as used for construction of
the signature is sufficient if the protocols used are unbiased and
appropriately powered.
We note that it is possible that gene selection and better
optimization/choice of classifiers could achieve predictivity and
power improvements over the protocol used in the present paper
[33]. For example, gene selection and error estimation using the
more sophisticated but computationally more demanding nested
cross-validation designs [43] was not pursued in order to keep the
computational requirements of running extensive permutation
tests under control.
We finally observe that the factors studied have been the subject
of substantial prior research in biostatistics and bioinformatics.
However their relationship to statistical power for molecular
signature testing has not been systematically investigated previ-
ously. For example, recent work has proposed a much-needed and
comprehensive set of guidelines for the analysis and reporting of
microarray and other ‘‘omics’’ data [4]. However the choice of
classifier is not addressed as of crucial importance, the choice of
error metric and estimator is not linked to statistical power, and
event balancing as a source of bias and low power is not addressed.
These omissions demonstrate the subtle effects of these factors on
statistical power and that these effects have gone largely unnoticed
in the field so far.
In conclusion, factors that affect the statistical power of complex
analysis protocols for molecular signature development from high-
Figure 2. Application of Protocol II to human microarray data. Each histogram is the distribution of the repeated 10-fold cross-validation AUC
estimates for each dataset under the null hypothesis ‘‘there is no signal present in the data’’ (as computed by 400 random outcome value
permutations). The red line in each graph is the observed value of AUC estimated by the repeated 10-fold cross-validation on the original data. AUC
and p-values are shown for each dataset in the embedded table. Bold p-values indicate that the null hypothesis is rejected at the 0.05 level in these
datasets.
doi:10.1371/journal.pone.0004922.g002
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present paper showed that choices of error metric, classifier, error
estimator and event balancing have large and compounding effects
on statistical power. They can further be combined with
inappropriate null hypotheses to yield ineffective analysis proto-
cols. An experimental comparison of data analysis protocols
reveals that previous highly-cited claims that microarray assays
may not be able to predict clinical outcomes better than chance
are byproducts of data analysis limitations. Research designs of
high-throughput studies will benefit by using the most powerful
data analysis protocols available combined with appropriate
statistical tests and doing so leads to substantial economies of
required sample. New data analysis protocols should be tested for
statistical efficiency before deploying for building molecular
signatures. We recommend testing against existing protocols (such
as one presented in this paper) in simulated or real data with
known predictive signal using datasets in which the experimenter
varies sample sizes [44,45].
Materials and Methods
Microarray Datasets
The characteristics of the human datasets analyzed [8,9,18–22]
are summarized in Table 1.
Error / prediction performance metric
The area under the receiver operating characteristic (ROC)
curve (AUC) is calculated by the formula provided in [46].
Proportion of misclassifications is calculated as the ratio:
number of wrong classification divided by total number of
classifications.
Classifiers & gene selection
Protocol I [23] involves selection of 50 genes with the highest
correlation in training data with outcome variable according to
Pearson’s correlation coefficient. Then molecular signatures are
developed based on these genes using a nearest-centroid prediction
method [47].
Protocol II uses the LibSVM implementation of Support Vector
Machines (SVMs) to build molecular signatures with a fixed
misclassification penalty parameter C=100, and a linear kernel
[48]. Gene selection is not employed to avoid increased
computational costs. We note that SVMs have built-in regulari-
zation however, which means that the learning algorithm
penalizes large weights of predictors thus favoring simpler models
by implicitly selecting genes, without using explicit gene selection
procedures [49,50].
Statistical analysis
Statistical significance of the molecular signatures in Protocol I
replicates the procedure of [23]. Namely, 500 training datasets of
size n are obtained by sampling without replacement the original
dataset (of size N) such that each training set has n/2 subjects with
each outcome. For each training set, the testing set is defined as its
complement (of size N-n). The molecular signatures are then fitted
on the training sets and their classification performance is assessed
on the corresponding testing sets. The above procedure is repeated
for different training set sizes ranging from 10 to a maximum value
which was chosen so that the testing set has at least one subject
representing each outcome. Given a distribution of classification
performances for each training set size, the corresponding 95%
intervals are constructed. The original dataset is considered to
contain predictive signal if the upper 95% interval limit is less than
0.5 proportion of misclassifications. Notice that the published
description of this method [23] does not explicitly state whether
the above condition for significance should hold in at least one
training set size n, or all possible training set sizes, or the majority
of them. Thus we examine all three possibilities in the present
work.
For Protocol II, we use outcome value-permutation to test in
each dataset the null hypothesis of no predictive signal [12,13].
This is also known as a randomization test or a Monte-Carlo
permutation test. We construct the distribution corresponding to
the null hypothesis by randomly permuting the values of the
outcome variable (400 times) and then using SVMs (as described
above) to compute the signature and repeated 10-fold cross-
validation estimate of AUC for each permuted dataset. The
repeated 10-fold cross-validation estimate from the original data is
then compared to this distribution, and p-values correspond to the
proportion of permuted estimators (under the null hypothesis) that
are more extreme than the repeated 10-fold cross-validation
estimate from the original (non-outcome value permuted) data.
Supporting Information
File S1 Comparison of proportion of misclassifications with area
under ROC curve (AUC)
Found at: doi:10.1371/journal.pone.0004922.s001 (0.06 MB
DOC)
File S2 Demonstration of pitfalls of non-balanced data
Found at: doi:10.1371/journal.pone.0004922.s002 (0.10 MB
DOC)
File S3 Details of simulation experiments
Found at: doi:10.1371/journal.pone.0004922.s003 (0.08 MB
DOC)
Table 1. Characteristics of gene expression microarray datasets analyzed in this study.
Dataset authors and
reference
Sample size and number of
events Number of variables (genes) Predicted event (outcome)
Beer et al [18] 86 (24 events) 7129 Lung adenocarcinoma survival
Bhattacharjee et al [19] 62 (31 events) 12600 Lung adenocarcinoma 4-year survival
Iizuka et al [21] 60 (20 events) 7070 Hepatocellular carcinoma 1-year recurrence-free survival
Pomeroy et al [22] 60 (21 events) 7129 Medulloblastoma survival
Rosenwald et al [20] 240 (138 events) 7399 Non-Hodgkin lymphoma survival
Veer et al [9] 97 (46 events) 24188 Breast cancer 5-year metastasis-free survival
Yeoh et al [8] 233 (32 events) 12240 Acute lymphocytic leukemia relapse-free survival
doi:10.1371/journal.pone.0004922.t001
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tion AUC estimates
Found at: doi:10.1371/journal.pone.0004922.s004 (0.08 MB
DOC)
File S5 Demonstration that Protocol II is not biased
Found at: doi:10.1371/journal.pone.0004922.s005 (0.09 MB
DOC)
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